Ekaterina A. Chingizova, Artur R. Chingizov, Ekaterina S. Menchinskaya, Evgeny A. Pislyagin, Aleksandra S. Kuzmich, Elena V. Leshchenko, Gleb V. Borkunov, Irina V. Guzhova, Dmitry L. Aminin, Ekaterina A. Yurchenko
{"title":"The influence of marine fungal meroterpenoid meroantarctine A toward HaCaT keratinocytes infected with Staphylococcus aureus","authors":"Ekaterina A. Chingizova, Artur R. Chingizov, Ekaterina S. Menchinskaya, Evgeny A. Pislyagin, Aleksandra S. Kuzmich, Elena V. Leshchenko, Gleb V. Borkunov, Irina V. Guzhova, Dmitry L. Aminin, Ekaterina A. Yurchenko","doi":"10.1038/s41429-024-00771-x","DOIUrl":"https://doi.org/10.1038/s41429-024-00771-x","url":null,"abstract":"<p>A new biological activity was discovered for marine fungal meroterpenoid meroantarctine A with unique 6/5/6/6 polycyclic system. It was found that meroantarctine A can significantly reduce biofilm formation by <i>Staphylococcus aureus</i> with an IC<sub>50</sub> of 9.2 µM via inhibition of sortase A activity. Co-cultivation of HaCaT keratinocytes with a <i>S. aureus</i> suspension was used as an in vitro model of skin infection. Treatment of <i>S. aureus-</i>infected HaCaT cells with meroantarctine A at 10 µM caused a reduction in the production of TNF-α, IL-18, NO, and ROS, as well as LDH release and caspase 1 activation in these cells and, finally, recovered the proliferation and migration of HaCaT cells in an in vitro wound healing assay up to the control level. Thus, meroantarctine A is a new promising antibiofilm compound which can effective against <i>S. aureus</i> caused skin infection.</p>","PeriodicalId":501839,"journal":{"name":"The Journal of Antibiotics","volume":"82 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142179619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Hashizume, Shigeko Harada, R. Sawa, K. Iijima, Y. Kubota, Y. Shibuya, Ryoko Nagasaka, Masaki Hatano, Masayuki Igarashi
{"title":"Correction: New chloptosins B and C from an Embleya strain exhibit synergistic activity against methicillin-resistant Staphylococcus aureus when combined with co-producing compound L-156,602.","authors":"H. Hashizume, Shigeko Harada, R. Sawa, K. Iijima, Y. Kubota, Y. Shibuya, Ryoko Nagasaka, Masaki Hatano, Masayuki Igarashi","doi":"10.1038/s41429-024-00722-6","DOIUrl":"https://doi.org/10.1038/s41429-024-00722-6","url":null,"abstract":"","PeriodicalId":501839,"journal":{"name":"The Journal of Antibiotics","volume":"36 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140965254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alison H. Araten, Rachel S. Brooks, Sarah D. W. Choi, Laura L. Esguerra, Diana Savchyn, Emily J. Wu, Gabrielle Leon, Katherine J. Sniezek, Mark P. Brynildsen
{"title":"Cephalosporin resistance, tolerance, and approaches to improve their activities","authors":"Alison H. Araten, Rachel S. Brooks, Sarah D. W. Choi, Laura L. Esguerra, Diana Savchyn, Emily J. Wu, Gabrielle Leon, Katherine J. Sniezek, Mark P. Brynildsen","doi":"10.1038/s41429-023-00687-y","DOIUrl":"https://doi.org/10.1038/s41429-023-00687-y","url":null,"abstract":"<p>Cephalosporins comprise a β-lactam antibiotic class whose first members were discovered in 1945 from the fungus <i>Cephalosporium acremonium</i>. Their clinical use for Gram-negative bacterial infections is widespread due to their ability to traverse outer membranes through porins to gain access to the periplasm and disrupt peptidoglycan synthesis. More recent members of the cephalosporin class are administered as last resort treatments for complicated urinary tract infections, MRSA, and other multi-drug resistant pathogens, such as <i>Neisseria gonorrhoeae</i>. Unfortunately, there has been a global increase in cephalosporin-resistant strains, heteroresistance to this drug class has been a topic of increasing concern, and tolerance and persistence are recognized as potential causes of cephalosporin treatment failure. In this review, we summarize the cephalosporin antibiotic class from discovery to their mechanisms of action, and discuss the causes of cephalosporin treatment failure, which include resistance, tolerance, and phenomena when those qualities are exhibited by only small subpopulations of bacterial cultures (heteroresistance and persistence). Further, we discuss how recent efforts with cephalosporin conjugates and combination treatments aim to reinvigorate this antibiotic class.</p>","PeriodicalId":501839,"journal":{"name":"The Journal of Antibiotics","volume":"79 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138818829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}